Replies to post #34179 on Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

About 20% present T315I in TKI-naive...

When randomized 50/50 this automatically reduces imatinib's MMR by half, or 10%, versus Pona. This also increases Pona's MMR by 7.5% since 75% of T315I patients achieved MMR in PACE trial.

So automatic 17.5% delta on MMR, and as you say throw in a few more of the 49 additional mutations shown to be resistant to imatinib but sensitive to Ponatinib and voila...its EPIC!